Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 18 04:00PM ET
2.11
Dollar change
-0.13
Percentage change
-5.80
%
IndexRUT P/E- EPS (ttm)-2.75 Insider Own37.56% Shs Outstand22.25M Perf Week-6.64%
Market Cap47.05M Forward P/E- EPS next Y-3.31 Insider Trans0.00% Shs Float13.92M Perf Month-16.93%
Income-61.06M PEG- EPS next Q-0.76 Inst Own52.62% Short Float2.38% Perf Quarter-40.90%
Sales0.00M P/S- EPS this Y83.91% Inst Trans-1.84% Short Ratio3.56 Perf Half Y-36.83%
Book/sh7.42 P/B0.28 EPS next Y49.45% ROA-38.30% Short Interest0.33M Perf Year-
Cash/sh7.50 P/C0.28 EPS next 5Y55.36% ROE-249.02% 52W Range2.13 - 15.24 Perf YTD-27.24%
Dividend Est.- P/FCF- EPS past 5Y- ROI-36.99% 52W High-86.15% Beta-
Dividend TTM- Quick Ratio17.03 Sales past 5Y0.00% Gross Margin- 52W Low-0.94% ATR (14)0.21
Dividend Ex-Date- Current Ratio17.03 EPS Y/Y TTM- Oper. Margin- RSI (14)38.46 Volatility9.89% 8.20%
Employees72 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price16.33
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-25.24% Payout- Rel Volume0.71 Prev Close2.24
Sales Surprise- EPS Surprise1.00% Sales Q/Q- EarningsNov 07 AMC Avg Volume92.90K Price2.11
SMA20-9.83% SMA50-16.24% SMA200-49.65% Trades Volume69,267 Change-5.80%
Date Action Analyst Rating Change Price Target Change
Dec-13-24Downgrade Guggenheim Buy → Neutral
Apr-22-24Initiated Piper Sandler Overweight $20
Apr-22-24Initiated Leerink Partners Outperform $25
Apr-22-24Initiated Guggenheim Buy $24
Feb-03-25 10:00AM
Dec-12-24 04:01PM
Nov-25-24 07:00AM
Nov-07-24 04:01PM
Nov-05-24 07:00AM
08:00AM Loading…
Oct-14-24 08:00AM
Sep-11-24 07:00AM
Aug-13-24 04:28AM
03:32AM
Aug-12-24 10:53PM
04:01PM
Jun-05-24 07:00AM
May-13-24 02:53PM
07:00AM
May-06-24 08:00AM
10:05AM Loading…
May-01-24 10:05AM
Apr-14-24 11:37AM
Apr-11-24 08:00AM
Apr-08-24 08:00AM
Mar-27-24 06:55PM
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burow KristinaDirectorApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
CRANDELL KEITH10% OwnerApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
ARCH Venture Fund IX, L.P.10% OwnerApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 02 '24Buy16.00312,5005,000,0001,884,787Apr 04 04:15 PM